Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

Demographic and psychosocial factors associated with the decision to learn mutation status in familial frontotemporal dementia and the impact of disclosure on mood
Bajorek, Lynn, Kiekhofer, Rachel, Hall, Matthew J. , Taylor, Joanne, Lucente, Diane , Brushaber, Danielle , Coppolla, Giovanni, Bordelon, Yvette , Dickerson, Brad C., Fagan, Anne M. , Fields, Julie A. , Forsberg, Leah K. , Galasko, Doug, Gavrilova, Ralitza H. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Graff‐Radford, Jonathan, Grant, Ian , Heuer, Hilary W. , Huey, Edward D. , Kornak, John , Ljubenkov, Peter A. , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F. , Miyagawa, Toji , Onyike, Chiadi U. , Pedraza, Otto , Petrucelli, Leonard , Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Rascovsky, Katya, Ritter, Aaron, Savica, Rodolfo , Toga, Arthur W. , Weıntraub, Sandra , Boxer, Adam L. , Rosen, Howard J. , Staffaroni, Adam M. , Hall, Matthew, Appleby, Brian S. , Botha, Hugo , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Fong, Jamie , Foroud, Tatiana , Goldman, Jill , Graff‐Radford, Jonathan , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Huang, Eric J. , Irwin, David J. , Jones, David T. , Kantarci, Kejal , Kremers, Walter K. , Lapid, Maria I. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , McMillan, Corey T. , Miller, Bruce L. , Pascual, Belén , Rexach, Jessica E. , Roberson, Erik D. , Rojas, Julio C. , Seeley, William W. , Tartaglia, Maria Carmela , Wong, Bonnie , Wszołek, Zbigniew K. , VandeVrede, Lawren , Boeve, Bradley F.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S7 | Pages: No page available

10.1002/alz.050692 Get It

AbstractBackgroundUp to 30% of frontotemporal dementia (FTD) cases are due to known pathogenic mutations (f‐FTD). Little is known about the factors that predict who will choose to learn their results. Upcoming clinical trials in f‐FTD may require disclosure prior to enrollment, even before symptom onset, and thus characterizing this sample is important. Furthermore, understanding the mood impacts of genetic disclosure may guide genetic counseling practice.MethodF‐FTD participants (n=568) from families with a known pathogenic mutation (MAPT, C9orf72, GRN) were enrolled through the ARTFL/LEFFTDS Longitudinal FTD Study (ALLFTD) and provided the opportunity for disclosure. Independent‐sample t‐tests compared demographic and psychosocial factors between participants who did and did not receive their results. In participants who were asymptomatic at baseline and follow up (n=199,177 with follow‐up), linear mixed effects modeling was used to investigate pre‐ to post‐disclosure changes in the 15‐item Geriatric Depression Scale (GDS).ResultOf participants from families with a known pathogenic genetic mutation, 47% received genetic disclosure. Of the asymptomatic subset (n=386), 36% know their mutation status. Of these asymptomatic learners, 46% received disclosure through the study, and the remainder learned their genetic status prior to study enrollment. None of the analyzed demographic or psychosocial factors (i.e., sex, age, education, having children) differed between learners and non‐learners (p’s > 0.05). In the longitudinal analysis of asymptomatic participants, learners showed a pre‐ to post‐increase of 0.31 GDS points/year (95%CI: ‐0.08, 0.69, p = 0.12), whereas non‐learners showed a slight decline (‐0.15 points/year, 95%CI: ‐0.36, 0.06, p = 0.16). This difference between slopes was statistically significant (0.46, 95%CI: 0.02, 0.89, p=0.04) but represents a small clinical effect. In asymptomatic learners, slopes did not differ based on mutation status (0.28, 95%CI: ‐0.66, 1.20, p=0.55). Conclusions were based on the estimates and full range of confidence intervals.ConclusionThe majority of asymptomatic research participants do not know their genetic status, which will be a consideration for clinical trials that require disclosure. No considered demographic factors were strongly associated with the decision to receive disclosure. The findings suggest that disclosure in asymptomatic participants has minimal impact on depressive symptoms regardless of genetic results.
Gearing up for the future: Exploring facilitators and barriers to inform clinical trial design in frontotemporal lobar degeneration
Banga, Yasmin B, Lai, Yujung, Kim, Priscilla , Boxer, Adam L. , Rosen, Howard J. , Forsberg, Leah K. , Heuer, Hilary W. , Brushaber, Danielle , Bordelon, Yvette , Dickerson, Brad C., Dickinson, Susan, Faber, Kelley , Fagan, Anne M. , Fields, Julie A. , Fishman, Ann, Galasko, Doug, Gavrilova, Ralitza H. , Geschwind, Daniel H. , Ghoshal, Nupur , Graff‐Radford, Jonathan, Graff‐Radford, Neill R. , Grant, Ian , Huey, Edward D. , Karydas, Anna M., Kaufer, Daniel , Kramer, Joel H. , Kornak, John , Lagone, Emma, Ljubenkov, Peter A. , Lucente, Diane , Mackenzie, Ian R. , Manoochehri, Masood , Masdeu, Joseph C. , McGinnis, Scott, Mendez, Mario F, Miyagawa, Toji , Nelson, K. , Onyike, Chiadi U. , Pantelyat, Alex, Pearlman, Rodney , Petrucelli, Leonard , Rademakers, Rosa , Ramos, Eliana Marisa , Rankin, Katherine P. , Rascovsky, Katya, Ritter, Aaron, Sabbagh, Marwan N. , Salmon, David P. , Savica, Rodolfo , Staffaroni, Adam M. , Syrjanen, Jeremy A. , Tatton, Nadine , Taylor, Jack C. , Weıntraub, Sandra , Wheaton, Diana, Wong, Benjamin , Boeve, Bradley F. , Appleby, Brian S. , Biernacka, Joanna M. , Botha, Hugo , Bozoki, Andrea C , Brannelly, Patrick , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Foroud, Tatiana , Gendron, Tania F. , Goldman, Jill , Graff‐Radford, Jonathan , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Huang, Eric J. , Irwin, David J. , Jones, David T. , Kantarci, Kejal , Knopman, David S. , Kremers, Walter K. , Kukull, Walter A. , Léger, Gabriel C. , Litvan, Irene , Masdeu, Joseph C , Mendez, Mario F, Miller, Bruce L. , Nelson, Kevin M, Pascual, Belén , Pottier, Cyril , Rexach, Jessica E. , Roberson, Erik D. , Rojas, Julio C. , Seeley, William W. , Tartaglia, Maria Carmela , Toga, Arthur W. , Wszołek, Zbigniew K.

Mayo Clinic

Alzheimer's & Dementia | February 1, 2022 | Volume: 17 | Issue: S7 | Pages: No page available

10.1002/alz.052495 Get It

AbstractBackgroundFrontotemporal lobar degeneration (FTLD) refers to a group of neurodegenerative conditions, affecting the frontal and/or temporal lobes. Ongoing research has provided insight into developing clinical trials for FTLD and key clinical measures such as structural MRI. To inform clinical trial design and optimize participation, it is imperative to explore facilitators and barriers for potential candidates.ObjectiveThe objective of this study is to explore facilitators and barriers to participating in future clinical trials for FTLD.MethodsAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) and Longitudinal Evaluation of Familial Frontotemporal Dementia Subjects (LEFFTDS) are observational studies focused on characterizing FTLD syndromes in preparation for clinical trials. The 584 participants enrolled across 18 research sites in the United States and Canada completed a survey assessing interest in clinical trial participation.Results29% of respondents self‐reported as patients (63±10 years), 26% self‐reported as caregivers answering on behalf of patients (65±10 years), and 45% self‐reported as healthy but at risk for FTLD (48±14 years). Travel reimbursement was the most common factor reported to positively influence participation (≧66%), with the healthy but at risk group showing the strongest endorsement (83%). Cost and time involved in travel were possible barriers for about half of the patients (48%) and healthy but at risk respondents (53%). The respondents value receiving feedback on the study findings (≧80%) and being informed of their individual disease progression (≧75%). Particularly, keeping participation confidential was very important for the healthy but at risk group (62%). In regard to research assessments, most participants demonstrated a high interest in physical and neurological exams at a research center (≧87%) whereas only half were interested in doing more invasive procedures such as the lumbar puncture (≧52%). Overall, respondents showed a positive attitude and support for research participation (≧77%) and trusted that their health information would remain confidential in a clinical trial (≧53%).ConclusionsFavorable attitudes and interest towards medical research exist among participants. To optimize participation, clinical trials should allocate funding for travel and involve participants in feedback about study results and their disease progression. Alternatives to invasive assessments may increase participation.
Recommended Musculoskeletal and Sports Ultrasound Terminology: A Delphi‐Based Consensus Statement
Hall, Mederic M. , Allen, Georgina , Allison, Sandra J. , Craig, Joseph G. , DeAngelis, Joseph P. , Delzell, Patricia B. , Finnoff, Jonathan T. , Gupta, Atul , Hoffman, Douglas F. , Nazarian, Levon N. , Onishi, Kentaro , Ray, Jeremiah W. , Smith, Jay , Tagliafico, Alberto , Allen, Georgina M , Allison, Sandra , Craig, Joseph , Frank, Rachel M , Gupta, Atul , Hoffman, Douglas F , Jacobson, Jon A , Narouze, Samer , Nazarian, Levon N , Onishi, Kentaro , Ray, Jeremiah W , Sconfienza, Luca M , Smith, Jay , Tagliafico, Alberto , Finnoff, Jonathan T , Jacobson, Jon A. , Narouze, Samer

Mayo Clinic

Journal of Ultrasound in Medicine | February 1, 2022 | Volume: 41 | Issue: 10 | Pages: 2395-2412

10.1002/jum.15947 | PMID 35103998 Get It

Objectives The current lack of agreement regarding standardized terminology in musculoskeletal and sports ultrasound presents challenges in education, clinical practice, and research. This consensus was developed to provide a reference to improve clarity and consistency in communication. Methods A multidisciplinary expert panel was convened consisting of 18 members representing multiple specialty societies identified as key stakeholders in musculoskeletal and sports ultrasound. A Delphi process was used to reach consensus which was defined as group level agreement >80%. Results Content was organized into seven general topics including: 1) General Definitions, 2) Equipment and Transducer Manipulation, 3) Anatomic and Descriptive Terminology, 4) Pathology, 5) Procedural Terminology, 6) Image Labeling, and 7) Documentation. Terms and definitions which reached consensus agreement are presented herein. Conclusions The historic use of multiple similar terms in the absence of precise definitions has led to confusion when conveying information between colleagues, patients, and third‐party payers. This multidisciplinary expert consensus addresses multiple areas of variability in diagnostic ultrasound imaging and ultrasound‐guided procedures related to musculoskeletal and sports medicine.
Is the presence of tumor‐infiltrating lymphocytes predictive of outcomes in patients with melanoma?
Morrison, S. , Vetto, John T. , Fowler, Graham, Leong, Stanley P. L. , Kashani–Sabet, Mohammed , Pockaj, Barbara A. , Sondak, Vernon K. , Messina, Jane L. , Mozzillo, Nicola, Schneebaum, Schlomo , Han, Dale , Group, for the Sentinel Lymph Node Working, Morrison, Steven L , Kashani-Sabet, Mohammed , Sondak, Vernon K , Han, Gang , Elenwa, Faith , Kosiorek, Heidi , Zager, Jonathan S. , Group, for the Sentinel Lymph Node Working

Mayo Clinic

Cancer | February 1, 2022 | Volume: 128 | Issue: 7 | Pages: 1418-1428

10.1002/cncr.34013 | PMID 35103302 Get It

BackgroundThe significance of tumor‐infiltrating lymphocytes (TILs) in melanoma is debated. This article presents a multicenter, retrospective study assessing the predictive and prognostic value of TILs.MethodsThe Sentinel Lymph Node Working Group database was queried from 1993 to 2018 for cases with known TIL data. TILs were categorized as absent or present, which included nonbrisk (NB), brisk (B), and present but unspecified TIL levels. Clinicopathologic factors were correlated with TILs, sentinel lymph node (SLN) status, and melanoma‐specific survival (MSS).ResultsOverall, 3203 patients were included. The median thickness was 1.5 mm, and 469 cases had SLN metastases. TILs were present in 2458 cases (76.7%), with NB, B, and unspecified TILs seen in 1691 (68.8%), 691 (28.1%), and 76 (3.1%), respectively. Multivariable analysis showed that the presence of TILs significantly predicted a negative SLN biopsy (P < .05). The median follow‐up was 25.2 months. MSS was significantly better for cases with TILs than cases without TILs (P < .001). According to multivariable analysis, age, gender, thickness, mitotic rate, ulceration, lymphovascular invasion, and SLN status were significantly prognostic of MSS (all P values < .05). Although TILs were not prognostic of MSS, when multiple imputation was used and the SLN status was excluded, the presence of TILs was significantly prognostic of improved MSS (hazard ratio, 0.78; 95% confidence interval, 0.64‐0.95; P = .0154).ConclusionsTILs are a favorable marker because their presence significantly predicts a negative SLN, and the absence of TILs may be a prognostic marker of worse survival in patients with a positive SLN but not a negative SLN. TILs may also serve as a prognostic marker of survival when the SLN status is not considered.
Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk
Jack, Clifford R. , Therneau, Terry M. , Lundt, Emily S. , Wiste, Heather J. , Mielke, Michelle M. , Graff‐Radford, Jonathan , Lowe, Val J. , Vemuri, Prashanthi , Gunter, Jeffrey L. , Petersen, Ronald C. , Graff-Radford, Jonathan , Vemuri, Prashanthi , Jack, Clifford R , Mielke, Michelle M , Knopman, David S. , Schwarz, Christopher G. , Senjem, Matthew L. , Lundt, Emily S

Mayo Clinic

Brain Communications | January 31, 2022 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcac017 | PMID 35310829 Get It

Abstract Dementia and mortality rates rise inexorably with age and consequently interact. However, because of the major logistical difficulties in accounting for both outcomes in a defined population, very little work has examined how risk factors and biomarkers for incident dementia are influenced by competing mortality. The objective of this study was to examine long-term associations between amyloid PET, APOE ɛ4, sex, education and cardiovascular/metabolic conditions, and hazard and absolute risk of dementia and mortality in individuals without dementia at enrolment. Participants were enrolled in the Mayo Clinic Study of Aging, a population-based study of cognitive ageing in Olmsted County, MN, USA. All were without dementia and were age 55–92 years at enrolment and were followed longitudinally. Predictor variables were amyloid PET, APOE ɛ4 status, sex, education, cardiovascular/metabolic conditions and age. The main outcomes were incident dementia and mortality. Multivariable, multi-state models were used to estimate mortality and incident dementia rates and absolute risk of dementia and mortality by predictor variable group. Of the 4984 participants in the study, 4336 (87%) were cognitively unimpaired and 648 (13%) had mild cognitive impairment at enrolment. The median age at enrolment was 75 years; 2463 (49%) were women. The median follow-up time was 9.4 years (7.5 years after PET). High versus normal amyloid (hazard ratio 2.11, 95% confidence interval 1.43–2.79), APOE ɛ4 (women: hazard ratio 2.24, 95% confidence interval 1.80–2.77; men: hazard ratio 1.37, 95% confidence interval 1.09–1.71), older age and two additional cardiovascular/metabolic conditions (hazard ratio 1.37, 95% confidence interval 1.22–1.53) were associated with the increased hazard of dementia (all P &lt; 0.001). Among APOE ɛ4 carriers with elevated amyloid, remaining lifetime risk of dementia at age 65 years was greater in women [74% (95% confidence interval 65–84%) high and 58% (95% confidence interval 52–65%) moderate amyloid], than men [62% (95% confidence interval 52–73%) high and 44% (95% confidence interval 35–53%) moderate amyloid]. Overall, the hazard and absolute risk of dementia varied considerably by predictor group. The absolute risk of dementia associated with predictors characteristic of Alzheimer’s disease was greater in women than men while at the same time the combination of APOE ɛ4 non-carrier with normal amyloid was more protective in women than men. This set of findings may be attributed in part to different biological effects and in part to lower mortality rates in women.
Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey
Harkins, R. Andrew , Patel, Sharvil , Lee, Michelle J. , Switchenko, Jeffrey M. , Ansell, Stephen M. , Bartlett, Nancy L. , Blum, Kristie A. , Cashen, Amanda F. , Casulo, Carla , Friedberg, Jonathan W. , Johnston, Patrick B. , Leonard, John P. , Link, Brian K. , Lossos, Izidore S. , Martin, Peter , Maurer, Matt, Mehta–Shah, Neha , Koff, Jean L. , Flowers, Christopher R. , Patel, Sharvil P , Kahl, Brad S , Link, Brian K , Lossos, Izidore S , Maurer, Matthew , Mehta-Shah, Neha , Westin, Jason R , Koff, Jean L , Bartlett, Nancy L , Switchenko, Jeffrey , Casulo, Carla , Kahl, Brad S. , Reagan, Patrick Michael , Westin, Jason R.

Mayo Clinic

Blood Advances | January 31, 2022 | Volume: 6 | Issue: 9 | Pages: 2745-2756

10.1182/bloodadvances.2021006504 | PMID 35100356 Get It

Abstract Recent first-line randomized controlled trials (RCTs) for patients with diffuse large B-cell lymphoma (DLBCL) have shown negative results, which may be due in part to onerous eligibility criteria limiting enrollment of poor-risk patients who require immediate treatment. We conducted a Delphi-method survey with lymphoma experts in the United States to define recommendations for essential and potentially unnecessary enrollment criteria for modern first-line DLBCL RCTs aimed at increasing clinical diversity of ensuing study groups. We first tabulated enrollment criteria from 19 DLBCL RCTs spanning the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) era to identify common eligibility criteria from prior DLBCL RCTs for inclusion in the Delphi-method survey. We tabulated 451 total eligibility criteria comprising 51 criterion categories across 19 first-line DLBCL RCTs in the R-CHOP era. We then surveyed lymphoma clinical trial experts representing 8 academic medical centers in the United States regarding essential and unnecessary eligibility criteria for modern DLBCL RCTs. Seventeen of 29 invited clinical investigators completed the round-1 questionnaire (response rate, of 58.6%), 15 of 17 round-1 participants (88.2%) completed the round-2 survey, and all round-1 participants reviewed finalized recommendations for eligibility criteria for modern first-line DLBCL RCTs. We defined consensus recommendations for 31 modernized eligibility criteria including threshold values for 10 quantitative eligibility criteria aimed at facilitating enrollment of a clinically diverse study population in first-line DLBCL RCTs designed to improve standard-of-care therapy.
Sex-specific lesion pattern of functional outcomes after stroke
Bretzner, Martin , Hong, Sung‐Min , Schirmer, Markus D. , Cohen, Alexander L. , Regenhardt, Robert W. , Donahue, Kathleen, Nardin, Marco, Etherton, Mark R. , Hancock, Brandon L., Mocking, Steven J. T. , McIntosh, Elissa C. , Benavente, Oscar, Donatti, Amanda , Heitsch, Laura , Jiménez-Conde, Jordi , Kittner, Steven J. , Levi, Christopher , Rolfs, Arndt , Schmidt, Reinhold , Sharma, Pankaj , Słowik, Agnieszka , Söderholm, Martin , Sousa, Alessandro , Stanne, Tara M. , Strbian, Daniel , Thijs, Vincent , Wassélius, Johan , Woo, Daniel , Zand, Ramin , McArdle, Patrick F. , Worrall, Bradford B. , Maguire, Jane , Fox, Michael , Bzdok, Danilo , Wu, Ona , Rost, Natalia S. , Bretzner, Martin , Cohen, Alexander , Etherton, Mark R , Jood, Katarina , Lemmens, Robin , Strbian, Daniel , Regenhardt, Robert W , Wu, Ona , Zand, Ramin , Bonkhoff, Anna K. , Dalca, Adrian Vasile , Giese, Anne‐Katrin , Attia, John , Bevan, Steve , Cole, John W. , Griessenauer, Christoph J. , Holmegaard, Lukas , Lemmens, Robin , McDonough, Caitrin W. , Meschia, James F. , Phuah, Chia‐Ling , Ropele, Stefan , Rosand, Jonathan M. , Roquer, Jaume , Rundek, Tatjana , Sacco, Ralph L. , Tatlisumak, Turgut , Vagal, Achala , Jern, Christina , Lindgren, Arne G.

Mayo Clinic

Brain Communications | January 31, 2022 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcac020 | PMID 35282166 Get It

Abstract Stroke represents a considerable burden of disease for both men and women. However, a growing body of literature suggests clinically relevant sex differences in the underlying causes, presentations and outcomes of acute ischaemic stroke. In a recent study, we reported sex divergences in lesion topographies: specific to women, acute stroke severity was linked to lesions in the left-hemispheric posterior circulation. We here determined whether these sex-specific brain manifestations also affect long-term outcomes. We relied on 822 acute ischaemic patients [age: 64.7 (15.0) years, 39% women] originating from the multi-centre MRI-GENIE study to model unfavourable outcomes (modified Rankin Scale &gt;2) based on acute neuroimaging data in a Bayesian hierarchical framework. Lesions encompassing bilateral subcortical nuclei and left-lateralized regions in proximity to the insula explained outcomes across men and women (area under the curve = 0.81). A pattern of left-hemispheric posterior circulation brain regions, combining left hippocampus, precuneus, fusiform and lingual gyrus, occipital pole and latero-occipital cortex, showed a substantially higher relevance in explaining functional outcomes in women compared to men [mean difference of Bayesian posterior distributions (men – women) = −0.295 (90% highest posterior density interval = −0.556 to −0.068)]. Once validated in prospective studies, our findings may motivate a sex-specific approach to clinical stroke management and hold the promise of enhancing outcomes on a population level.
Association ofBDNFVal66Met With Tau Hyperphosphorylation and Cognition in Dominantly Inherited Alzheimer Disease
Barthélemy, Nicolas R. , Goate, Alison , Hassenstab, Jason , Fagan, Anne M. , Xiong, Chengjie , Cruchaga, Carlos , Farlow, Martin R. , Graff‐Radford, Neill R. , Laske, Christoph , Masters, Colin L. , Salloway, Stephen , Morris, John C. , Bateman, Randall J. , Network, Dominantly Inherited Alzheimer, Chhatwal, Jasmeer P. , Fitzpatrick, Colleen , Bodge, Courtney, Cruz, Chrismary De La, Mejia, Arlene, Neimeyer, Katie, Gardener, Samantha L. , Taddei, Kevin , Ping, Lingyan, Seyfried, Nick , Gräber‐Sultan, Susanne, Häsler, Lisa M., Käser, Stephan, Kuder-Buletta, Elke, Preische, Oliver, Diffenbacher, Anna, Igor, Yakushev, Levin, Johannes, Vöglein, Jonathan , Obermüller, Ulricke, Esposito, Bianca, Goate, Alison, Buck, Jill , Farlow, Marty, Chrem, Patricio, Egido, Noelia , Haass, Christian , Nuscher, Brigitte , Day, Gregory S. , Graham, Morgan, Stephens, Sochenda, Bechara, Jacob , Araki, Aki, Ishii, Kenji , Senda, Michio , Ihara, Ryoko , Nagamatsu, Akemi, Fox, Nick C. , Mummery, Cath, Goldberg, Sarah B. , Ikonomović, Snežana, Mountz, James M. , Nadkarni, Neelesh K. , Patira, Riddhi , Smith, Lori, Snitz, Beth E. , Thompson, Sarah , Weamer, Elise A., Mason, Neal Scott, Chui, Helena, Ringman, John M. , Adams, Sarah , Brandon, Susan E. , Buckles, Virginia, Cash, Lisa, Chen, Charlie, Chua, Jasmin, Cruchaga, Carlos, Denner, Darcy, Dincer, Aylin , Donahue, Tamara, Feldman, Becca , Franklin, Erin , Friedrichsen, Nelly, Gonzalez, Alyssa, Gray, Julia, Gremminger, Emily, Groves, Alex, Hassenstab, Jason, Hellm, Cortaiga, Herries, Elizabeth, Hoechst-Swisher, Laura, Hornbeck, Russ C. , Jerome, Gina, Keefe, Sarah , Koudelis, Deb, Martinez, Rita, Mawuenyega, Kwasi G., McCullough, Austin , McDade, Eric, Norton, Joanne, Perrin, Richard J. , Shady, Kristine, Sigurdson, Wendy, Xu, Jinbin , Cruchaga, Carlos , Day, Gregory S , Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Lim, Yen Ying , Maruff, Paul , Sato, Chihiro , Benzinger, Tammie L.S. , Xiong, Chengjie , Schofield, Peter R. , McDade, Eric , Network, Dominantly Inherited Alzheimer, Fitzpatrick, Colleen, Goldman, Jill , Noble, James M. , Martins, Ralph N. , Sohrabi, Hamid R. , Carter, Kathleen, Duong, Duc M , Johnson, Erik C. B. , Levey, Allan I. , Ping, Lingyan, Hofmann, Anna, Jucker, Mathias , Levin, Johannes, Goate, Alison, Renton, Alan , Brosch, Jared R. , Buck, Jill, Ghetti, Bernardino , Allegri, Ricardo , Morenas‐Rodríguez, Estrella , Jack, Clifford R. , Brooks, William S. , Ikeuchi, Takeshi , Kasuga, Kensaku , Fujii, Hisako , Shimada, Hiroyuki , Niimi, Yoshiki , Douglas, Jane, Grilo, Miguel, O’Connor, Antoinette , Koeppe, Robert A. , Berman, Sarah , Klunk, William E. , López, Oscar L. , Brandon, Susan, Cruchaga, Carlos, Feldman, Becca, Flores, Shaney , Gordon, Brian A. , Hassenstab, Jason, Holtzman, David M. , Karch, Celeste M. , Li, Yan , Marsh, Jacob, McDade, Eric, Smith, Jennifer A. , Wang, Peter , Wang, Qing , Xu, Xiong

Mayo Clinic

JAMA Neurology | January 31, 2022 | Volume: 79 | Issue: 3 | Pages: 261

10.1001/jamaneurol.2021.5181 | PMID 35099506 Get It

International Center-Level Variation in Utilization of Completion Lymph Node Dissection and Adjuvant Systemic Therapy for Sentinel Lymph Node-Positive Melanoma at Major Referral Centers
Broman, Kristy K., Hughes, Tasha M., Bredbeck, Brooke C., Sun, James, Kirichenko, Dennis, Carr, Michael J., Sharma, Avinash, Bartlett, Edmund K., Nijhuis, Amanda A.G., Thompson, John F., Hieken, Tina J., Kottschade, Lisa, Downs, Jennifer, Gyorki, David E., Stahlie, Emma, Akkooi, Alexander van, Ollila, David W., O’shea, Kristin, Song, Yun, Karakousis, Giorgos, Moncrieff, Marc, Nobes, Jenny, Vetto, John, Han, Dale, Hotz, Meghan, Farma, Jeffrey M., Deneve, Jeremiah L., Fleming, Martin D., Perez, Matthew, Baecher, Kirsten, Lowe, Michael, Bagge, Roger Olofsson, Mattsson, Jan, Lee, Ann Y., Berman, Russell S., Chai, Harvey, Kroon, Hidde M., Teras, Juri, Teras, Roland M., Farrow, Norma E., Beasley, Georgia M., Hui, Jane Yuet Ching, Been, Lukas, Kruijff, Schelto, Sinco, Brandy, Sarnaik, Amod A., Sondak, Vernon K., Zager, Jonathan S., Dossett, Lesly A., Hui, Jane Yuet Ching , Dossett, Lesly A. , Akkooi, Alexander C. J. van , Bagge, Roger Olofsson , Kroon, Hidde M. , Hui, Jane Yuet Ching , Olofsson Bagge, Roger , Broman, Kristy K., Hughes, Tasha M., Bredbeck, Brooke C. , Sun, James, Kirichenko, Dennis, Carr, Michael J., Sharma, Avinash, Bartlett, Edmund K., Nijhuis, Amanda A.G., Thompson, John F., Hieken, Tina J., Kottschade, Lisa, Downs, Jennifer, Gyorki, David E., Stahlie, Emma, Ollila, David W., O’shea, Kristin, Song, Yun, Karakousis, Giorgos, Moncrieff, Marc, Nobes, Jenny, Vetto, John, Han, Dale, Hotz, Meghan, Farma, Jeffrey M., Deneve, Jeremiah L., Fleming, Martin D., Perez, Matthew, Baecher, Kirsten, Lowe, Michael, Mattsson, Jan, Lee, Ann Y., Berman, Russell S., Chai, Harvey, Teras, Juri, Teras, Roland M., Farrow, Norma E., Beasley, Georgia M., Hui, Jane Yuet Ching, Been, Lukas, Kruijff, Schelto, Sinco, Brandy, Sarnaik, Amod A., Sondak, Vernon K., Zager, Jonathan S.

Mayo Clinic

Annals of Surgery | January 29, 2022 | Volume: 277 | Issue: 5 | Pages: e1106-e1115

10.1097/sla.0000000000005370 | PMID 35129464 Get It

Objective: The aim of this study was to determine overall trends and center-level variation in utilization of completion lymph node dissection (CLND) and adjuvant systemic therapy for sentinel lymph node (SLN)-positive melanoma. Summary Background Data: Based on recent clinical trials, management options for SLN-positive melanoma now include effective adjuvant systemic therapy and nodal observation instead of CLND. It is unknown how these findings have shaped practice or how these contemporaneous developments have influenced their respective utilization. Methods: We performed an international cohort study at 21 melanoma referral centers in Australia, Europe, and the United States that treated adults with SLN-positive melanoma and negative distant staging from July 2017 to June 2019. We used generalized linear and multinomial logistic regression models with random intercepts for each center to assess center-level variation in CLND and adjuvant systemic treatment, adjusting for patient and disease-specific characteristics. Results: Among 1109 patients, performance of CLND decreased from 28% to 8% and adjuvant systemic therapy use increased from 29 to 60%. For both CLND and adjuvant systemic treatment, the most influential factors were nodal tumor size, stage, and location of treating center. There was notable variation among treating centers in management of stage IIIA patients and use of CLND with adjuvant systemic therapy versus nodal observation alone for similar risk patients. Conclusions: There has been an overall decline in CLND and simultaneous adoption of adjuvant systemic therapy for patients with SLN-positive melanoma though wide variation in practice remains. Accounting for differences in patient mix, location of care contributed significantly to the observed variation.
Lifestyle modifications and complementary treatments for hidradenitis suppurativa
De, Devea R. , Rick, Jonathan W. , Shih, Terri , Hsiao, Jennifer L. , Hsiao, Jennifer L , Alavi, Afsáneh , Shi, Vivian Y.

Mayo Clinic

Dermatological Reviews | January 28, 2022 | Volume: 3 | Issue: 3 | Pages: 126-136

10.1002/der2.117 Get It

AbstractBackgroundHidradenitis suppurativa (HS) is a chronic inflammatory dermatosis with recurrent painful nodules and abscesses affecting the intertriginous areas. Patients often experience a significant negative impact on quality of life from associated pain, discharge, odor, scarring, and social stigma. Even with complex medical regimens, patients may report inadequate disease control. Lifestyle changes and complementary and alternative medicines (CAM) are used by a majority of HS patients. Conventional medicines and lifestyle and CAM modalities strategically incorporated together can increase treatment satisfaction and success.ObjectiveWe aim to highlight lifestyle and CAM treatment modalities to use alongside conventional treatment plans for HS patients.FindingsLifestyle modifications for HS patients include weight loss, reducing skin friction, smoking cessation, and stress reduction. Dietary modifications for HS patients include limiting foods containing dairy, Brewer's yeast, and simple carbohydrates, appropriate caloric reduction, and consuming foods in the Mediterranean diet. The CAM modalities studied in HS are vitamin D, niacinamide, vitamin B12, zinc, and magnesium. Potential CAM modalities for HS include probiotics, cannabinoids, turmeric, bathing regimens, and acupuncture.ConclusionThis review is a guide for clinicians to provide evidence‐based care for HS patients seeking non‐pharmacologic treatment modalities such as weight loss, clothing choices, dietary changes, and use of supplements and complementary medicine. Lifestyle and CAM modalities may be used in parallel with conventional medicines to synergistically improve patient disease outcomes.